Impact of CMV infection through the first year post living donor renal allo-transplantation on patient and graft outcome

Cytomegalovirus (CMV) infection is the single most frequent infectious complicationin renal transplant recipients. CMV infections were associated with decreased patient survival, graftsurvival.Methods: This single-center, retrospective study includes 611 patients who received renal allotransplantationfrom January 2003 to December 2009 at Mansoura Urology and Nephrology Center.We detected that 62 (10%) patients were infected with CMV disease (study group), this group wascompared with 62 patients were not infected with CMV disease (control group) .all the patientsdidn’t receive any prophylaxis for CMV.CMV PCR was used to diagnose CMV disease posttransplantation.Results: the Prevalence of CMV disease was 10% .pre-transplant CMV IgG was positive in bothgroups, in both donor and recipient. The mean onset for CMV disease was 71±48 days posttransplantation. In our study (40.7%) of patients who received Alemtuzumab (Campath- 1H)developed CMV disease, compared to (6.9%) to those who received Basiliximab. Acute rejectionthrough the first year post transplantation in CMV infected patients was significant (p-value 0.03).There was significant difference regarding graft survival (p-value >0.05) and patient survival (p-value>0.05) between study and control group, both patient and graft survival were significantly lower inthe CMV diseased group.